Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials (Q33891037)

29 July 2017

0 references

Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials (English)

1 reference

29 July 2017

1 reference

2

Ralf-Harto Hübner

1 reference

29 July 2017

Daniel Binder

1

1 reference

29 July 2017

Bettina Temmesfeld-Wollbrück

series ordinal

3

1 reference

29 July 2017

Peter Schlattmann

series ordinal

4

1 reference

29 July 2017

6 May 2011

1 reference

Cancer Chemotherapy and Pharmacology

29 July 2017

1 reference

29 July 2017

68

1 reference

29 July 2017

6

1 reference

29 July 2017

1575-1583

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1648-2

29 July 2017

0 references

cites work

Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Severe interstitial pneumonitis associated with the administration of taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Fatal pulmonary toxicity resulting from treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A report on serious pulmonary toxicity associated with gemcitabine-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Radiation recall pneumonitis induced by gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Combination Treatment with Weekly Docetaxel and Gemcitabine for Advanced Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status: Results of a Minnie Pearl Cancer Research Network Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase I study of gemcitabine and docetaxel for advanced stage solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Coo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1648-2

10.1007/S00280-011-1648-2

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference